Loading…
Clinical-stage biotech developing fast-acting psychedelic-derived (5-MeO-DMT) treatments for treatment-resistant depression.
Clinical-stage biotech developing fast-acting psychedelic-derived (5-MeO-DMT) treatments for treatment-resistant depression.
Has no medicine on sale, so it funds trials from money raised from investors, and revenue would arrive only after approval or a licensing deal. The business rests on one lead drug in one form of depression, so trial results move the whole company.
Moat: none (IP / patents). Pre-commercial; must navigate a novel regulatory path for a psychedelic-derived psychiatric drug.
Headquarters: Dublin, Ireland · Founded: 2018 · Employees: 73
Size GH Research (GHRS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.28B, the 2096th largest of 3,117 United States companies the cockpit tracks. Shares closed at $18.61 on 6 Nov 2026.
Performance Over six months the shares fell 13.1%, against -10.9% for the median peer and -1.1% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Short interest Short interest is 2.9% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$359,000 | -$335,000 | -$315,000 | -$315,000 | -$47,000 |
| EBITDA | -$71.1M | -$60.3M | -$49.9M | -$40.9M | -$30.5M |
| Net income | -$62.3M | -$48.3M | -$39.0M | -$35.6M | -$22.5M |
| Free cash flow | -$52.5M | -$43.7M | -$42.3M | -$33.4M | -$26.3M |
| Capital expenditure | $139,151 | $121,000 | $49,000 | $100,000 | $67,000 |
| Total debt | $360,000 | $512,000 | $624,000 | $974,000 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| GH Research GHRS | $1.28B | -13% | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | $1.22B | -13% | n/a | n/a | n/a | n/a |
| AtaiBeckley ATAI | n/a | +81% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GHRS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.0% | -6.2% | 9th lowest of 21 |
| 6-month return | -13.1% | -10.9% | 10th lowest of 21 |
| Distance from 52-week high | -40.8% | -42.6% | 11th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | 13.3× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% | +18.1% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | 111.4× | n/a | n/a |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | 4.0× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 36.2× | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 3.5× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |